| Literature DB >> 33033067 |
Jung Ho Kim1, Hi Jae Lee2, Nam Su Ku3, Seung Hyun Lee4, Sak Lee2, Jun Yong Choi1, Joon-Sup Yeom1.
Abstract
OBJECTIVE: The treatment of infective endocarditis (IE) has become more complex with the current myriad healthcare-associated factors and the regional differences in causative organisms. We aimed to investigate the overall trends, microbiological features, and outcomes of IE in South Korea.Entities:
Keywords: endocarditis; valve disease surgery
Year: 2020 PMID: 33033067 PMCID: PMC7788257 DOI: 10.1136/heartjnl-2020-317265
Source DB: PubMed Journal: Heart ISSN: 1355-6037 Impact factor: 5.994
Figure 1Flow of patients suspected of having infective endocarditis during the study period.
Clinical characteristics and outcomes of patients with IE
| Total (N=419) | |
| Demographics | |
| Age (years) | 56 (43–68) |
| Age ≥65 years | 138 (32.9) |
| Male sex | 275 (65.6) |
| Nosocomial infection | 91 (21.7) |
| Comorbidities | |
| Previous valve surgery | 83 (19.8) |
| Diabetes | 77 (18.4) |
| Antibiotic treatment within 30 days | 74 (17.7) |
| Cancer | 54 (12.9) |
| Renal disease | 43 (10.3) |
| Central venous catheter access | 32 (7.6) |
| Congestive heart failure | 29 (6.9) |
| Liver disease | 27 (6.5) |
| Haemodialysis | 23 (5.5) |
| Previous IE | 21 (5.0) |
| Cardiac device | 19 (4.5) |
| Immunosuppressive therapy | 18 (4.3) |
| Connective tissue disease | 15 (3.6) |
| Chemotherapy within 30 days | 15 (3.6) |
| Charlson Comorbidity Index | 2 (0–4) |
| Clinical symptoms and signs | |
| Fever | 310 (74.0) |
| Sepsis, including septic shock | 294 (70.2) |
| Left ventricular dysfunction | 141 (33.7) |
| Neurological complications | 129 (30.8) |
| Peripheral embolic complications | 35 (8.4) |
| Signs of peripheral vasculitis | 9 (2.1) |
| Outcomes | |
| Acute renal failure | 62 (14.8) |
| New-onset heart failure | 58 (13.8) |
| New-onset conduction abnormality | 32 (7.6) |
| In-hospital mortality | 61 (14.6) |
| 30-day mortality | 37 (8.8) |
| 1-year mortality | 73 (17.4) |
Data are presented as median (IQR) or number (%) of patients.
IE, infective endocarditis.
Echocardiographic and laboratory findings in patients with infective endocarditis
| Total (N=419) | |
| Affected valve | |
| Mitral valve | 257 (61.3) |
| Aortic valve | 181 (43.2) |
| Tricuspid valve | 34 (8.1) |
| Pulmonary valve | 16 (3.8) |
| Multiple valves | 70 (16.7) |
| Prosthetic valve | 63 (15.0) |
| Paravalvular complications | 68 (16.2) |
| Associated ventricular septal defect | 11 (2.7) |
| Vegetation size (cm) | 1.1 (0.7–1.6) |
| Preoperative laboratory findings (normal range) | |
| White blood cell count, ×103 (4.0–10.8) | 9.54 (6.92–12.95) |
| Segmented neutrophil (%) (39.0–74.0) | 79.4 (70.3–86.5) |
| Platelet count, 103/μL (150.0–400.0) | 202 (133–280) |
| Erythrocyte sedimentation rate (mm/hour) (0.0–15.0) | 61 (36–83) |
| C reactive protein (mg/L) (0.0–8.0) | 46.8 (10.3–103.0) |
| Procalcitonin, ng/mL (0.00–0.50) | 0.35 (0.16–1.13) |
| Severity scales | |
| SOFA score | 1 (1–3) |
| APACHE-II score | 6 (4–9) |
Data are presented as median (IQR) or number (%) of patients. Normal range refers to the hospital criteria.
APACHE, acute physiology and chronic health evaluation; SOFA, sequential organ failure assessment.
Figure 2Trends in the incidence and mortality rate of infective endocarditis according to calendar year in Poisson log-linear regression. Trends are depicted as green dashed lines.
Figure 3Distribution of microorganisms causing infective endocarditis according to calendar year. CNS, coagulase-negative staphylococci; GNB, Gram-negative bacillus; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus.
Indications, timing and outcomes in 273 patients who underwent surgery for infective endocarditis
| Total (N=273) | |
| Surgical indications | |
| Congestive heart failure | 217 (79.5) |
| Prevention of embolism | 101 (37.0) |
| Paravalvular complications | 58 (21.2) |
| Uncontrolled infections | 19 (7.0) |
| Pacemaker infections | 7 (2.6) |
| Valve locations | |
| Mitral valve | 174 (63.7) |
| Aortic valve | 131 (48) |
| Tricuspid valve | 17 (6.2) |
| Pulmonary valve | 10 (3.7) |
| Multiple valves | 56 (20.5) |
| Timing of surgery | |
| Surgery within 24 hours | 12 (4.4) |
| Surgery within 2–7 days | 110 (40.3) |
| Surgery at >7 days | 151 (55.3) |
| EuroSCORE II (%) | 6.2 (4.7–9.3) |
| Replaced valve | |
| Mechanical valve | 184 (67.4) |
| Bioprosthetic valve | 68 (24.9) |
| Bentall operation | 5 (1.8) |
| Homograft | 3 (1.1) |
| Valve repair only | 18 (6.6) |
| Outcomes | |
| New-onset heart failure | 32 (11.7) |
| Acute renal failure | 29 (10.6) |
| New-onset conduction abnormality | 27 (9.9) |
| In-hospital mortality | 20 (7.3) |
| 30-day mortality | 10 (3.7) |
| 1-year mortality | 21 (7.7) |
Data are presented as median (IQR) or number (%) of patients.
Figure 4Kaplan-Meier curves of the long-term survival rates of patients with infective endocarditis who underwent surgery versus those who underwent medical treatment only.
Changes in the timing of surgery according to calendar year
| Total | 2005–2012 | 2013–2017 | P value | |
| No. of patients who underwent surgery | 273 (100.0) | 137 (100.0) | 136 (100.0) | |
| Surgery within 7 days | 122 (44.7) | 40 (29.2) | 82 (60.3) | <0.001* |
| Days from diagnosis to surgery | 8.0 (4.0–17.0) | 11.0 (5.0–22.5) | 6.0 (4.0–11.0) | <0.001† |
| In-hospital mortality | 20 (7.3) | 13 (9.5) | 7 (5.1) | 0.169* |
Data are presented as a median (IQR) or number (%) of patients.
*χ2 test.
†Mann-Whitney U-test.